Physician profile
David Nava
NPI 1083234371
$2,085.02
in general payments reported to CMS, 2019-2025
20 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $729 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $244.90 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $193.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.84 | 2024-2025 | Jardiance |
| Amgen INC. | $135.75 | 2024 | Repatha, Otezla |
| Tg Therapeutics, INC. | $124.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $121.20 | 2023 | Xarelto |
| Sumitomo Pharma America, INC. | $95.23 | 2023-2025 | Gemtesa |
| Philips North America LLC | $53.09 | 2024-2025 | Ecc Solutions, (Ck6) Holter |
| Lilly USA, LLC | $47.85 | 2023-2024 | Mounjaro |
| Pfizer INC. | $40.96 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $35.16 | 2024 | Breztri |
| Merck Sharp & Dohme LLC | $33.59 | 2025 | Capvaxive, Gardasil 9 |
| Vertex Pharmaceuticals Incorporated | $30.31 | 2025 | |
| Aimmune Therapeutics, INC. | $28.72 | 2025 | Vowst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.52 | 2025 | Arexvy, Trelegy Ellipta |
| Seqirus USA INC | $20.15 | 2025 | Flucelvax, Fluad |
| Mannkind Corporation | $16.22 | 2024 | |
| Abbott Laboratories | $15.12 | 2025 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $7.52 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.